723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study

Ignace Vergote, Bradley J. Monk, R.E. O’Cearbhaill, Anneke M. Westermann, Susana Banerjee, Dearbhaile Catherine Collins, Mansoor Raza Mirza, David M. O’Malley, Christine Gennigens, Sandro Pignata, Bohuslav Melichar, Azmat Sadozye, Frédéric Forget, Krishnansu S. Tewari, Eelke Gort, Ibrahima Soumaoro, Camilla Mondrup Andreassen, Leonardo Nicacio, Els Van Nieuwenhuysen, Domenica Lorusso